Heidelberg University at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Heidelberg University takes part in 3 sessions at ESMO 2026 in Madrid. Its sessions centre on antibody-drug conjugates in gynaecological cancers, covering treatment sequencing in ovarian cancer and current evidence in endometrial cancer. It also covers immune-modulating approaches in neuro-oncology.

OrganizationESMO 2026 Attendance
Heidelberg University
Heidelberg, Germany
uni-heidelberg.de
University & institute
Public research university in Heidelberg, Germany, with medical faculties in Heidelberg and Mannheim.
Satellite
Fri Oct 23
10:25–10:50
New ADC Horizons: Sequencing Strategies, Emerging Therapies, and the Next Frontier in
AbbVie - Riding the Wave of Innovation Towards Personalized Medicine in Ovarian Cancer
Gynaecological cancers
Talk
Fri Oct 23
14:10–14:30
Current evidence and development of ADCs in EC
Update on the mangement of endometrial cancer in the era of molecular classification
Gynaecological cancers
Talk
Fri Oct 23
16:15–16:35
Presentation by Expert
The best is yet to come: Immune modulating approaches in neuro- oncology
Sarcoma, CNS, head & neck and rare cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Heidelberg University

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction